Well, I’m not too sure about this bounce being sustained.
No real news relation to the product or Novartis. So, same old management and treatments with, how should I say this, same “controversial” evidence of effectiveness. No news there.
So what do we have? Another completely different company with a completely different product gets approved. So all the specs come out because they are convinced if one dodgy approval can get over the line, then by gum so can ours.
My bet, if there is no further substantive news, it’ll bounce up for a bit then drift down.
Mesoblast in Freefall, page-638
-
- There are more pages in this discussion • 345 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |